(NVH)-lesioned rats show schizophrenia-like behaviors including cognitive impairment(1).We recently developed a novel cognitive enhancer,ST101,which is under investigation of clinical trial PhaseⅡ(2).Here,we define the mechanism underlying cognitive impairment of NVH-lesioned rats and test whether ...
- 《Clinical Infectious Diseases An Official Publication of the Infectious Diseases Society of America》 被引量: 170发表: 2010年 Comparison of the Toxicity of Amphotericin B in 5% Dextrose with That of Amphotericin B in Fat Emulsion in a Randomized Trial with Cancer Patients A multicentric ...
Clinical, radiological ... D Gladman - 《Q J Med》 被引量: 1072发表: 1987年 Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of ps... Psoriasis is a common, chronic, inflammatory, ...
Background We recently developed novel cognitive enhancer, ST101 (spiro[imidazo[1,2- 伪 ] pyridine-3,2-indan ] 2(3 H)-one) which is under investigation of clinical trial phase 2 in United State as Alzheimer therapeutics. The impaired neurogenesis in olfactory bulbectomized (OBX) mice was...
Clinical trial information: NCT04478279.Phase 1 pts demonstrating clinical benefit (SD, PR, CR). Dose (mg/kg) Tumor type Response Duration (weeks) 0.5 Signet ring adenocarcinoma SD 77+ 2 Small bowel adenocarcinoma SD 18 2 Abdominal sarcoma SD 9 4 Cutaneous melanoma PR 42+ 6 Hepatocellular ...
Trial Registration ClinicalTrials. gov Identifier: NCT04478279 References Homma J, Yamanaka R, Yajima N, Tsuchiya N, Genkai N, Sano M, Tanaka R. Increased expression of CCAAT/enhancer binding protein correlates with prognosis in glioma patients. Oncology Reports 2005;15:595–601. Ruffell D, Mour...
The integrated model provides a useful tool to characterize and predict the ST101 dose-response relationship, provide a quantitative rationale for dose selection in a phase 2 clinical trial and supports the continued development of ST101 as a potent peptide therapeutic for patients with solid tumors...
clinical trialPhase IIdonepezilBackground and Objective: ST101, an acetylcholine release agent with efficacy in rodent memory and cognition models, was assessed for clinical safety and efficacy.Gauthier, SergeSonexa Therapeut IncRountree, Susan
After the DLT evaluation for the DEP, enrollment for the ExP began in March 2023 in Japan, Singapore, Taiwan and Australia, and for the DEP for Chinese pts is also ongoing in China to evaluate tolerability and efficacy of this combination.Clinical trial information: NCT05245968.Hidekazu Hirano...